Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data
Background: Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS.Methods: According to the FDA’s Adverse Event Report...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.872854/full |
| _version_ | 1818010503184646144 |
|---|---|
| author | Ming Ni Ming Ni Xue-Dong Yin Xue-Dong Yin Wen-Juan Hu Na Zeng Bin Zhao Zhi-Ling Li |
| author_facet | Ming Ni Ming Ni Xue-Dong Yin Xue-Dong Yin Wen-Juan Hu Na Zeng Bin Zhao Zhi-Ling Li |
| author_sort | Ming Ni |
| collection | DOAJ |
| description | Background: Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS.Methods: According to the FDA’s Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated.Results: 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45–64 years) than other age groups, and less common in underage children (<18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45–74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2–7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4–20) (Mann-Whitney test, p < 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS.Conclusion: The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs. |
| first_indexed | 2024-04-14T05:56:10Z |
| format | Article |
| id | doaj.art-82e4191988ce47e6a72d416b36e8e4f6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-14T05:56:10Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-82e4191988ce47e6a72d416b36e8e4f62022-12-22T02:08:55ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-04-011310.3389/fphar.2022.872854872854Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance DataMing Ni0Ming Ni1Xue-Dong Yin2Xue-Dong Yin3Wen-Juan Hu4Na Zeng5Bin Zhao6Zhi-Ling Li7Department of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Clinical Pharmacy, Shaoxing Maternity and Child Health Care Hospital, Shaoxing, ChinaDepartment of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, ChinaShanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, ChinaBackground: Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS.Methods: According to the FDA’s Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated.Results: 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45–64 years) than other age groups, and less common in underage children (<18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45–74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2–7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4–20) (Mann-Whitney test, p < 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS.Conclusion: The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs.https://www.frontiersin.org/articles/10.3389/fphar.2022.872854/fullvancomycinlinezolidepidemiologySJSadverse event reporting system |
| spellingShingle | Ming Ni Ming Ni Xue-Dong Yin Xue-Dong Yin Wen-Juan Hu Na Zeng Bin Zhao Zhi-Ling Li Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data Frontiers in Pharmacology vancomycin linezolid epidemiology SJS adverse event reporting system |
| title | Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data |
| title_full | Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data |
| title_fullStr | Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data |
| title_full_unstemmed | Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data |
| title_short | Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data |
| title_sort | stevens johnson syndrome following vancomycin and linezolid a real world analysis of post marketing surveillance data |
| topic | vancomycin linezolid epidemiology SJS adverse event reporting system |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.872854/full |
| work_keys_str_mv | AT mingni stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT mingni stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT xuedongyin stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT xuedongyin stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT wenjuanhu stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT nazeng stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT binzhao stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata AT zhilingli stevensjohnsonsyndromefollowingvancomycinandlinezolidarealworldanalysisofpostmarketingsurveillancedata |